Abstract: A hetrazepine of the formula given below and a pharmaceutical composition comprising a therapeutically effective amount of the hetrazepine and a pharmaceutically acceptable inert carrier are disclosed and are useful in treating disease in a warm-blooded animal induced by endogenously formed PAF; ##STR1## wherein the substituents are defined herein.

Abstract: The present invention relates to thienodiazepines of formula Ib: ##STR1## wherein U, V, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. This invention also relates to processes for preparing these thienodiazepines and their use in pharmaceutical compositions with PAF-antagonistic activity.

Abstract: The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Abstract: The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Abstract: New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

Abstract: There is provided an improved blade for a fork lift truck, the blade helping to prevent damage to pallets or other objects. The blade includes a freely rotatable member mounted at the distal end of the blade, the rotatable member being mounted to at least partially protrude beyond the distal end and the member being rotatable about an axis which is substantially normal to the longitudinal axis of the blade.

Abstract: Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:R.sub.2 is a C.sub.1 -C.sub.4 alkyl group;R.sub.3 tetrahydropyran-4-yl or 1,3-dithiolan or;R.sub.3 represents one of the groups of formula ##STR2## and pharmaceutically acceptable acid addition salts thereof. These are adenosine antagonists, capable of acting as cholinomimetics, useful for the treatment of CNS disorders such as senile dementia and Alzheimer's disease.

Abstract: The invention relates to new pseudopeptides having an antiviral action, oft he general formula (I) ##STR1## with the meanings given in the description for the substituents, to a process for their preparation and to their use as antiviral agents, in particular against cytomegaloviruses.

Abstract: The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.

Abstract: An electro-optical scanner, particularly for position-, angle- and rotation-measuring instruments as well as for optical storages, comprising an illuminated or transilluminated code carrier (5), at least one optically scannable code track on the code carrier, an optical system (7) recording the code track, and an electro-optical sensor (8), with the optical system reproducing the code track on a light-sensitive surface of the sensor, should be easily manufactured, installed and adjusted, should comprise reduced dimensions, especially a smaller working distance and should allow a better position information. Thereto, the optical system comprises at least one rod-shaped lens (13) or a micro-lens plate.

Abstract: The invention relates to new diazephines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, processes for preparing them and their use as pharmaceutical compositions useful for treating PAF-induced disease.

Abstract: The invention relates to new thieno-triazolo-1,4-diazepino-2-carboxylic acid amides of formula I ##STR1## wherein R.sub.1 represents hydrogen, a C.sub.1 -C.sub.4 straight-chained or branched alkyl which can optionally be substituted by halogen, preferably Cl or Br, or by hydroxy, cyclopropyl, C.sub.1 -C.sub.3 alkoxy, preferably methoxy, or halogen, preferably chlorine or bromine;R.sub.2 and R.sub.3, each independently, represent hydrogen, a C.sub.1 -C.sub.4 straight-chained or branched alkyl, C.sub.1 -C.sub.4 hydroxyalkyl or the two groups R.sub.2 and R.sub.3 together with the nitrogen atom represent a 5-, 6- or 7-membered ring which optionally contains a nitrogen, oxygen or sulfur atom as a further heteroatom, the second nitrogen atom optionally being substituted by a C.sub.1 -C.sub.4 alkyl, preferably a methyl group;R.sub.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms; R.sub.2 is 2-, 3- or 4-pyridyl, phenyl or mono- or di-substituted phenyl, where the substituents are each individually alkoxy of 1 to 2 carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, alkyl or 1 to 4 carbon atoms, hydroxyl or nitro; andR.sub.3 and R.sub.4 are each independently hydrogen or alkyl of 1 to 4 carbon atoms; orR.sub.3 and R.sub.4, together with each other and the nitrogen atom to which they are attached, form an unsubstituted or methyl-substituted, saturated 5- or 6-membered heterocycle which may contain an additional oxygen or nitrogen heteroatom, or form an imidazole ring;where the aminomethyl substituent is attached to the 4- or 5-position or the pyrrolidine ring, and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as nootropics and antihypoxics.

Abstract: Laminates of improved edge strength have a foam or honeycomb core layer A comprising a heat resistant plastic and cover layers B comprising fiber reinforced heat resistant plastic, at least one edge of the core layer being joined to a foam strip C of a heat resistant thermoplastic material whose density is higher than the density of the core.

Abstract: Laminates with stable attachment areas have a foam or honeycomb core layer A comprising a heat resistant plastic and cover layers B comprising fiber reinforced heat resistant plastic, the core layer having at least one foam insert C of a heat resistant thermoplastic material whose density is higher than the density of the core.

Abstract: The invention relates to new 1,4-diazepines of the general formula ##STR1## in which R.sub.1, R.sub.2 R.sub.3, X and A have the meaning indicated in the specification.The new compounds are intended for use for the treatment of pathological states and diseases in which PAF (platelet activating factor) is involved.

Abstract: A process for the preparation of expandable granules based on polyaryl ether sulfones and/or polyether imides, containing from 5 to 20% by weight of a physical blowing agent, the blowing agent and the polymers being mixed in an extruder and subsequently extruded directly into a medium at less than 40.degree. C., and a process for the production of foams from expandable granules based on polyaryl ether sulfones and/or polyether imides, containing from 5 to 20% by weight of a physical blowing agent, the granules being press molded at from 120.degree. to 250.degree. C. and at a pressure of from 5 to 30 bar to form a sheet, and the sheet being subsequently foamed by reducing the pressure, are described.